AstraZeneca Reports 9M and Q3 2026 Results
AstraZeneca said revenue rose 7% and Core EPS increased 14% in the first nine months of 2026, at constant exchange rates.
Story updates
11:04:27 AM UTC
SquawkNews
AstraZeneca reported 9M 2026 revenue up 7% and Core EPS up 14% at CER, and reaffirmed FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth.Material DetailsContext by AI AnalystThis is mid-cycle confirmation of growth with reiterated guidance and pipeline…